Theravance Inc. (THRX)
-NasdaqGS 35.34 
0.37(1.04%) 12:36PM EDT - Nasdaq Real Time Price
| Prev Close: | 35.71 |
|---|
| Open: | 35.64 |
|---|
| Bid: | 35.33 x 500 |
|---|
| Ask: | 35.35 x 400 |
|---|
| 1y Target Est: | 47.33 |
|---|
| Beta: | 1.72 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 35.25 - 35.95 |
|---|
| 52wk Range: | 19.10 - 42.41 |
|---|
| Volume: | 166,211 |
|---|
| Avg Vol (3m): | 1,574,000 |
|---|
| Market Cap: | 3.51B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.51 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Is Elan Pushing Its Luck?at Motley Fool(Tue, Jun 18)
- Royalty Pharma abandons bid for Elanat Financial Times(Tue, Jun 18)
- Royalty drops hostile bid for Ireland's ElanReuters(Tue, Jun 18)
- Elan holders OK buyback, vote down 3 dealsAP(Mon, Jun 17)
- Theravance Larger Than S&P 500 Component E*trade Financial Corporationat Forbes(Mon, Jun 17)
- Elan Investors Approve Buyback to Force Royalty Bid Endat Bloomberg(Mon, Jun 17)
- Elan Explores Sale OptionsZacks(Mon, Jun 17)
- Elan Shareholders Bring Management To Heelat Investopedia(Mon, Jun 17)
- Theravance Will Split Into 2 Companies After Losing Elan Bidat Motley Fool(Mon, Jun 17)
- Theravance to proceed with plan to split businessAP(Mon, Jun 17)
- Elan Shareholders Do Not Approve Theravance/Elan Royalty Participation TransactionMarketwired(Mon, Jun 17)
- Elan Shareholder Vote Nixes Royalty Pharma Takeover -- For Nowat TheStreet(Mon, Jun 17)
- Royalty hostile bid for Elan in doubt after voteReuters(Mon, Jun 17)
- THERAVANCE INC Files SEC form 8-K, Other EventsEDGAR Online(Mon, Jun 17)
- Elan Inviting Royalty Pharma Bid Shows Hostility Easingat Bloomberg(Fri, Jun 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 355.04 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.77 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.46 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | 0.10 |
|---|
Business Summary
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)...
View More